On this page
A pituitary assessment asks whether a lesion affects hormone production, nearby structures or both. A symptom can be important without being specific to a pituitary tumor. Conversely, an unexpected scan finding can need assessment even when the person has not noticed an endocrine symptom.1
Different routes into assessment
Some people are investigated because of a possible hormone syndrome. Others have vision-related concerns or an image obtained for an unrelated reason. An incidental finding is not automatically an adenoma, and the presence of a lesion does not establish that it caused the reason the scan was requested. Its appearance, clinical context and endocrine evaluation must be considered together.1
The history helps a clinician separate a pattern of hormone excess, a possible deficiency and local effects. Pituitary hormones influence several other endocrine glands; that is why the assessment extends beyond simply measuring the tumor.2
How symptoms can differ
Local pressure can be associated with headache or loss of vision. Reduced pituitary hormone function may affect menstrual cycles or sexual function. Hormone-excess patterns differ: prolactin excess may bring milk discharge outside breastfeeding, growth-hormone excess can enlarge the hands and feet, and ACTH-related cortisol excess can cause easy bruising and changes in body shape. These are examples, not criteria for identifying a tumor.3
Some lesions cause no noticeable symptoms, and the same complaints can have other causes. Tell your clinician about persistent changes; the pattern, examination and testing determine the explanation.3
What each part contributes
| Part of assessment | Question it helps answer |
|---|---|
| History and examination | Is there a pattern suggesting hormone excess, deficiency or another explanation? |
| Clinician-selected hormone testing | Are pituitary pathways affected, and does a result need confirmation or further investigation? |
| Dedicated pituitary imaging when indicated | What is the nature, size and anatomical relationship of the finding? Has it changed? |
| Vision assessment when warranted | Are the optic pathways affected, including changes that a person may not notice? |
The 2025 incidentaloma guidance recommends endocrine evaluation at presentation, including consideration of both excess and deficiency. It also defines when specialist imaging and ophthalmic assessment are relevant. The tests address different questions; one normal result does not settle every part of the assessment.1
A laboratory value needs context
An elevated prolactin result can have causes other than a prolactinoma, including medication effects or disruption of pituitary stalk signaling. The prolactinoma consensus discusses this differential and the interpretation challenges in biochemical assessment. It is the clinician’s task to reconcile the result, history and imaging. Do not stop or change a medicine to “test” the explanation yourself.4
Similarly, testing for a particular hormone syndrome involves an appropriate clinical question and sometimes confirmation. Bringing the original report, units, dates and current medication list to the team is more useful than matching an isolated value to an internet rule.
Making sense of uncertainty
Ask what is known about the finding and what the next assessment is intended to resolve. A team may arrange surveillance when immediate treatment is not indicated, or seek further expertise if the lesion’s nature or management is unclear. The plan should explain how new symptoms, imaging changes or hormone findings would alter that decision.1
Children, pregnancy and possible inherited disease need their own assessment pathways.
Sudden severe symptoms
Seek immediate emergency assessment for sudden severe headache, particularly with new visual loss, double vision or reduced consciousness. Pituitary apoplexy is one possible emergency, and other serious causes can resemble it.56
References
- Fleseriu M et al. Nat Rev Endocrinol. 2025;21:638–655. Published 24 June 2025. doi:10.1038/s41574-025-01134-8. Source ↩
- National Cancer Institute. What Are Pituitary Tumors? Updated 28 March 2025. Source ↩
- National Cancer Institute. Pituitary Tumors Signs & Symptoms. Updated 28 March 2025. Source ↩
- Petersenn S et al. Nat Rev Endocrinol. 2023;19:722–740. doi:10.1038/s41574-023-00886-5. Read with Author Correction, 17 October 2023. Source ↩
- Baldeweg SE et al. Society for Endocrinology Endocrine Emergency Guidance. Endocr Connect. 2016;5:G12–G15. doi:10.1530/EC-16-0057. Source ↩
- Biagetti B et al. Eur J Endocrinol. 2026;194:R49–R66. Published 4 February 2026. doi:10.1093/ejendo/lvag034. PubMed ↩